Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984905 | 0.81 | VDR (0.46) | HDAC6HSD17B2HSD17B1MEN1MAPT | |
| SCHEMBL5539637 | 0.79 | MAOB (0.50) | MAPTRAB9AKMT2AGUSBGAA | |
| SCHEMBL5536101 | 0.79 | NPC1 (0.53) | MAPTRAB9ACYP1A2MAOB | |
| SCHEMBL9862893 | 0.78 | NPC1 (0.51) | HDAC6MAPTRAB9AKMT2AGAA | |
| SCHEMBL4418435 | 0.78 | BRD4 (0.57) | MEN1MAPTKMT2AGAA | |
| SCHEMBL436384 | 0.77 | GAA (0.57) | RAB9AGAA | |
| SCHEMBL1805431 | 0.76 | KDR (0.43) | GAA | |
| SCHEMBL11524334 | 0.76 | GAA (0.46) | MEN1RAB9AKMT2AGAAESR1 | |
| SCHEMBL9863203 | 0.76 | SNCA (0.46) | HSD17B2HSD17B1MEN1MAPTRAB9A | |
| SCHEMBL14266194 | 0.74 | RAB9A (0.51) | HDAC6HSD17B2HSD17B1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1776111-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060058301-A1 | Modulators of PPAR and methods of their preparation | METABOLEX, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2006020916-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, PPARA | HDAC6 1275/4885HSD17B2 251/4885HSD17B1 247/4885 |
| US-20060058301-A1 | Modulators of PPAR and methods of their preparation | PPARG, PPARD, PPARA | HDAC6 1275/4885HSD17B2 251/4885HSD17B1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.